Atesoglu, E. B. Et Al. 2023. Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data. HEMATOLOGICAL ONCOLOGY , vol.41, no.4 , 663-673.

Atesoglu, E. B., Gulbas, Z., Uzay, A., ÖZCAN, M., ÖZKALEMKAŞ, F., Dal, M. S., ... Kalyon, H.(2023). Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data. HEMATOLOGICAL ONCOLOGY , vol.41, no.4, 663-673.

Atesoglu, Elif Et Al. "Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data," HEMATOLOGICAL ONCOLOGY , vol.41, no.4, 663-673, 2023

Atesoglu, Elif B. Et Al. "Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data." HEMATOLOGICAL ONCOLOGY , vol.41, no.4, pp.663-673, 2023

Atesoglu, E. B. Et Al. (2023) . "Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data." HEMATOLOGICAL ONCOLOGY , vol.41, no.4, pp.663-673.

@article{article, author={Elif Birtas Atesoglu Et Al. }, title={Glofitamab in relapsed/refractory diffuse large B-cell lymphoma: Real-world data}, journal={HEMATOLOGICAL ONCOLOGY}, year=2023, pages={663-673} }